Eledon Pharmaceuticals (ELDN) Total Non-Current Liabilities (2015 - 2026)
Eledon Pharmaceuticals (ELDN) posted Total Non-Current Liabilities of $15.8 million for Q1 2026, down 23.94% on a QoQ basis from $20.8 million in Q4 2025, and up 32.78% year-over-year from $11.9 million in Q1 2025.
Eledon Pharmaceuticals (ELDN) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 32.78% year-over-year to $15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.8 million (up 32.78% YoY) and the FY2025 annual result came in at $20.8 million, up 44.54% from the prior year.
- Total Non-Current Liabilities was $15.8 million for Q1 2026 at Eledon Pharmaceuticals, down from $20.8 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $20.8 million in Q4 2025 and bottomed at $4.7 million in Q3 2023.
- A 5-year average of $11.6 million and a median of $11.9 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities slumped 34.41% — and 2024, when it soared 207.48%.
- Eledon Pharmaceuticals' Total Non-Current Liabilities stood at $8.6 million in 2022, then slumped by 34.41% to $5.6 million in 2023, then soared by 155.0% to $14.4 million in 2024, then jumped by 44.54% to $20.8 million in 2025, then slipped by 23.94% to $15.8 million in 2026.
- Business Quant data shows ELDN's Total Non-Current Liabilities at $15.8 million in Q1 2026, $20.8 million in Q4 2025, and $16.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 468.11 Bn | 463.32 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 122.48 Bn | 115.23 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.55 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 55.66 Bn | 50.47 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.42 Bn | 34.41 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Eledon Pharmaceuticals | 400.23 Mn | 400.23 Mn | - | 15.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.83 Mn |
| Dec 31, 2025 | 20.81 Mn |
| Sep 30, 2025 | 16.86 Mn |
| Jun 30, 2025 | 16.37 Mn |
| Mar 31, 2025 | 11.92 Mn |
| Dec 31, 2024 | 14.40 Mn |
| Sep 30, 2024 | 14.56 Mn |
| Jun 30, 2024 | 8.16 Mn |
| Mar 31, 2024 | 6.00 Mn |
| Dec 31, 2023 | 5.65 Mn |
| Sep 30, 2023 | 4.73 Mn |
| Jun 30, 2023 | 6.84 Mn |
| Dec 31, 2022 | 8.61 Mn |
| Dec 31, 2021 | 6.55 Mn |
| Dec 31, 2020 | 6.59 Mn |
| Dec 31, 2019 | 1.47 Mn |
| Dec 31, 2018 | 2.53 Mn |
| Dec 31, 2017 | 1.44 Mn |
| Sep 30, 2017 | 94,000.00 |
| Jun 30, 2017 | 245,000.00 |